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In the September 12, 2013 issue of Nature, the Epi4K Consortium (Allen et al., 2013) reported sequencing
264 patient trios with epileptic encephalopathies. The Consortium focused on genes exceptionally intolerant
to sequence variations and found substantial interconnections with autism and intellectual disability gene
networks.This is a particularly exciting time for the
genetics of the epilepsies, especially
considering its sordid history. For cen-
turies, epilepsy was considered a sign
of a supernatural presence, often of a
demonic variety. More than 2,000 years
ago, however, Hippocrates warned that
epilepsy was no more sacred than other
diseases and that its origins may lie in he-
redity. Yet, for many years, the epilepsies
were not considered of genetic origin and
up until the 20th century epileptics were
socially isolated. The strong genetic
component of epilepsy was suggested
by observation of familial aggregation,
confirmed by several monozygotic-dizy-
gotic twin studies, and in the 1990s, the
first epilepsy-specific genes were cloned,
encoding ion channels and neurotrans-
mitter receptors. Dominant and recessive
Mendelian inheritance patterns have been
verified for several of these, but it became
clear that these mutations are subject to
partial penetrance (i.e., not every personwith the mutation will develop epilepsy)
and that even if epilepsy develops in a
carrier, not everyone with the mutation
will display the same form of epilepsy.
Other types of genetic alterations, such
as de novo (sporadic) and somatic (limited
to specific brain areas) mutations were
long suspected to contribute to epilepsy
but not validated until recently. Whole-
exome sequencing (WES) provided a
new tool to understand this multifactorial
disorder, allowing a window into the
genetic architecture that for the first time
did not require pedigree and linkage
analysis.
Over the course of several years and
with generous support from the NINDS,
the Epilepsy Genome Phenome Program
(http://www.epgp.org) recruited hun-
dreds of patients and families from an
international network of 27 clinical centers
in the U.S., Europe, and Australia. The
goal of the EPGP program was to enroll
1,500 families in which two or moreaffecteds displayed epilepsy and 750
individuals with epileptic encephalopa-
thies (EEs). EEs are a group of progressive
partially overlapping neurological syn-
dromes in which patients, usually young
children, present with psychomotor dys-
functions and concurrent severe clinical
epilepsy, often with infantile spasms,
Lennox-Gastaut syndrome, polymicrogy-
ria, or periventricular heterotopias. The
EPGP cohorts were recruited, meticu-
lously phenotyped, and subsequently
underwent DNA exome sequencing
through the Epi4K consortium, again
funded by the NINDS. The results of the
first sequencing effort of the EEs were
recently published in the journal Nature
(Allen et al., 2013).
Following the idea that clinical homo-
geneity corresponds to genetic homoge-
neity, Allen et al. (2013) focused on two
well-described EEs: infantile spasms and
Lennox-Gastaut syndrome. Collectively,
they sequenced 264 patients and their80, October 2, 2013 ª2013 Elsevier Inc. 9
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Previewsparents (trios), as well as 600 control trios,
and analyzed the exome sequences,
hunting for de novo mutations. De novo
mutations are common, occurring on
average about once per generation in
the exome even in healthy individuals,
and mutation rates rise with increasing
parental age (Kong et al., 2012). De novo
mutations have been shown to contribute
to many neurodevelopmental disorders
such as intellectual disability and autism
spectrum disorders (Sanders et al.,
2012; Rauch et al., 2012), as well as other
diseaseswith reduced reproductive rates.
Allen et al. (2013) identified approximately
one de novo mutation per patient or
control, in agreement with previously
published rates (O’Roak et al., 2012),
and were left with the difficult task of
interpreting the results.
The power of large genetic studies is
that they can draw statistically significant
conclusions, but one of the biggest
challenges in analyzing whole-exome
sequencing data is to confidently priori-
tize potentially deleterious genetic vari-
ants. Here Allen et al. (2013) confirmed
that patients with EEs are more likely to
carry predicted loss-of-function muta-
tions than the controls, and then, using
available single-nucleotide polymorphism
data, calculated that de novo mutations
in EE patients are several times more
likely to occur in genes intolerant to
genomic sequence variations than in
controls. Indeed, based on their analysis,
the most commonly mutated epilepsy
genes appear to be extremely intolerant
to genomic changes. Both observations
may guide variant prioritization in future
humanwhole-exome sequencing studies.
Importantly, Allen et al. (2013) identified
seven recurrently mutated genes, hence
probably disease-causing, in 26 patients,
which accounted for 10% of total cases.
Among these genes, five were previously
linked to EEs and two were novel. Inter-
estingly, the two novel EE-causative
genes have been previously linked to
other neurological disorders. This was
not unexpected, because it is not rare
that genes in which mutations have been
first associated with a specific pheno-
type have been subsequently shown to
associate with a broader phenotypic
spectrum. Although not surprising, the
observation endorses the necessity of a
modification in the genetic diagnostic10 Neuron 80, October 2, 2013 ª2013 Elsevieapproach when dealing with neurodeve-
lopmental disorders. While, until a few
years ago, genetic analysis was concen-
trated on a restricted gene panel for
each specific syndromic disorder, it is
clear now that the future will need to
focus on the genome as a whole. As an
example, Yu and colleagues reported
earlier this year that exome analysis of a
cohort of families with autism uncovered
loss-of-function mutations in genes
already linked to highly syndromic pre-
sentations (Yu et al., 2013). The results
speak to the weakness in differentiating
clinical brain disorders but the strengths
of exome sequencing to distinguish these
same or genome approaches disorders
genetically. This observation may have
relevance to neurodevelopmental and
neuropsychiatric diseases in general.
In line with these previous observa-
tions, Allen et al. (2013) report that pa-
tients with de novo exonic mutations in
the GABRB3 gene—deletion of GABRB3
was already linked to epilepsy in Angel-
man syndrome—may present with non-
Angelman EE. These findings indicate
that in the absence of a deep understand-
ing of the molecular mechanisms under-
lying neurodevelopmental disorders and
of the precise function and operational
mode of the protein encoded by disor-
der-causative genes, it will be difficult
to make clinical diagnostic predictions
based solely on the patient genotype
and vice versa.
Although Allen et al. (2013) identified
several recurrently mutated genes, it
was perhaps not surprising that there
was also tremendous locus heterogeneity
suggested by the analysis, even in clini-
cally well-defined epilepsy syndromes.
Indeed, in the great majority of the
cases, Allen et al. (2013) identified private
genes (i.e., mutated in a single patient),
leaving to future genetic studies and
functional work to determine whether
these contribute to epilepsy.
At the same time, Allen et al. (2013)
suggest that genes seemingly diverse
in function may in fact be functionally
interconnected. Following this principle,
Allen et al. (2013) determined intercon-
nectivity between these private genes
and previously known epilepsy genes
and were successful in constructing a
unique network containing 71 nodes
(genes). This type of analysis, alreadyr Inc.demonstrated to be useful for other
neurological disorders (O’Roak et al.,
2012), is a profound advance as it pro-
vides evidence that many rare genetic
alterations may converge on a few key
biological processes. Identifying these
processes will be extremely important in
guiding future gene discoveries as well
as pathway-specific treatments.
Allen et al. (2013) also found significant
overlap between their gene network and
the autism spectrum disorder (ASD) and
intellectual disability gene networks previ-
ously published (Sanders et al., 2012;
O’Roak et al., 2012; Iossifov et al., 2012;
Neale et al., 2012; de Ligt et al., 2012).
This observation reinforces the idea that
epilepsy, autism, and intellectual disability
may share, at least in part, common path-
ophysiological mechanisms (Figure 1).
Some of the nodes of this network have
been previously identified as mutated
in forms of epilepsy with other genetic
architecture. Thus, genes mutated in
either de novo or inherited epilepsies
help to fill in the epilepsy network and
contribute separately or in conjunction
to the overall genetic risk of seizures.
For example, mutations in TNK2,
encoding a brain-expressed tyrosine
kinase, have been recently identified as
a very rare cause of autosomal recessive
early onset epilepsy (Hitomi et al., 2013),
and it directly interacts with the product
of NEDD4L, known to promote ubiqui-
tination and internalization of various
plasma channels, including sodium chan-
nels mutated in epilepsy. The Epi4K
paper (Allen et al., 2013) found a de
novo mutation in MTOR, a serine/threo-
nine kinase that plays roles in cell prolifer-
ation, cell size, survival, and metabolism.
Altered mTOR signaling has been found
in patients with focal cortical malforma-
tions associated with epilepsy (Aronica
et al., 2012), and MTOR, together with
other components of the PI3K-AKT-
mTORpathway, have been recently found
to harbor de novo somatic variants in
focal brain dysplasia and epilepsy (Lee
et al., 2012). The fact that somatic gain-
of-function mutations in components
of the PI3K-AKT-mTOR pathway have
been implicated in tumorigenesis might
suggest that similar etiologies are shared
by even a broader range of diseases.
Despite the presentation of mutations
in MTOR, DCX, or FLNA in the Epi4K
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Figure 1. Depiction of Overlapping Nodes of Genetic Mutation among EEs, ASD, and
Intellectual Disability
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Previewspaper, Allen et al. (2013) found no asso-
ciated structural brain malformations,
even though these genes are well known
to cause cortical dysplasias, possibly
explained by functional diversity of
human mutations. Different alleles in
the same gene might affect protein
function differently, which in turn might
directly relate to the severity of the
disease (i.e., gain-of-function versus
loss-of-function or hypermorphic versus
hypomorphic). The functional impact of
such mutations needs to be further vali-
dated in order to understand the mecha-
nisms of diseases.
In conclusion, this and other recent
publications reinforce the concept that
whole-exome sequencing is unquestion-
ably a powerful tool for dissecting the
genetic basis of diseases and traits notcompletely tractable to previous gene-
discovery strategies. Due to the extreme
locus heterogeneity and the hitherto
mentioned phenotypical variability, future
studies will undoubtedly coalesce pa-
tients with a range of clinical presenta-
tions rather than analyze very selective
collections. In addition, functional work
will be essential to prove the causative
role of private genes, to identify and
understand the implicated biological
pathways, to comprehend the structure-
function-phenotype relationship, and,
finally, to develop better treatments.REFERENCES
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